Medtronic Raises Fiscal 2027 Guidance on Strong Q1 Performance
Event summary
- Medtronic reported Q1 FY27 revenue of $9.8 billion, up 13.7% year-over-year, exceeding guidance by 200 basis points.
- Cardiovascular segment grew 18.9%, led by 88% growth in Cardiac Ablation Solutions.
- Company raised FY27 organic revenue growth guidance to 7.25%-7.75% and non-GAAP EPS guidance to $5.94-$6.00.
- Completed acquisitions of Scientia Vascular and SPR Therapeutics, Inc.
- Announced strategic partnerships with Affera and Cornerstone Robotics, and investment in Pi-Cardia.
The big picture
Medtronic's strong Q1 performance and raised guidance reflect its successful execution of targeted investments in innovation and portfolio development. The company's strategic focus on high-growth areas like cardiovascular and neuroscience technologies positions it well in the competitive medical device market. The recent acquisitions and partnerships further bolster its pipeline and market reach, supporting long-term value creation.
What we're watching
- Integration Challenges
- How Medtronic will integrate recent acquisitions and partnerships into its existing portfolio.
- Market Expansion
- Whether the company can sustain its strong growth across its cardiovascular and neuroscience segments.
- Regulatory Approvals
- The pace at which Medtronic can secure additional regulatory clearances for its innovative products.
Related topics